Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb (BMS) has reported net sales of $5.43bn for the second quarter ended 30 June 2011, an increase of 14% as compared to $4.77bn for the same period in 2010.
Subscribe to our email newsletter
Net earnings attributable to BMS were $902m, compared to $927m for the same period in the prior year.
For the six months ended 30 June 2011 net sales were $10.45bn, compared to $9.58bn for the same period in 2010.
The Net earnings attributable to BMS for the six months ended 30 June 2011 were $1.89bn as compared to $1.67bn for the same period prior year.
BMS CEO Lamberto Andreotti said while they delivered double-digit sales growth during the second quarter, driven in part by the initial performance of Yervoy (ipilimumab), they also received regulatory approval for Nulojix (belatacept) in the US and Europe, and Eliquis in Europe for VTE prevention.
"That brings us to three new products approved in three months, including the approval of YERVOY in the US in March," Andreotti said.